How does OncuraKit relate to mammography for breast cancer screening?

Mammography remains the standard-of-care breast cancer screening tool for average-risk women over 40. OncuraKit is designed as a complementary tool, not a replacement for mammography. It is particularly relevant for women who have received an inconclusive mammogram (BI-RADS 3 or 4 — 'probably benign' or 'suspicious') and want additional molecular information while awaiting a follow-up imaging appointment. Additionally, for women with dense breast tissue (where mammograms are less sensitive), a positive OncuraKit result provides an additional signal to support more aggressive follow-up. OncuraKit cannot confirm or rule out breast cancer — it can only indicate whether cancer-associated miRNA is elevated, which may influence the priority of follow-up steps.